All In Biotech

Drug Trial Radar · NCT04856982

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 158 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

158

Actual

Start

May 17, 2021

Primary completion

Aug 7, 2027

Study completion May 25, 2028

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene mutation. One of the causes of ALS is a change (or mutation) in the SOD1 gene, which causes abnormal SOD1 protein to be made. This abnormal protein can cause the motor neurons in people with ALS to break down and die. When neurons are damaged, they release a protein called neurofilament light chain, also known as NfL. Previous studies have shown that NfL levels are higher in people with SOD1-ALS, even before any ALS symptoms appear. In this study, researchers will look at the effect of tofersen treatment in the earlier stages of the disease, even before ALS symptoms appear. Researchers believe that giving tofersen to patients as early as possible may slow the onset of ALS symptoms and the progression of the disease. This study will have 4 parts. In Part A, participants will have their health monitored and NfL levels tested on a monthly basis, but they will not receive any study drug. Tofersen or placebo will be given to participants in Parts B, while all participants will receive tofersen in Parts C and D. The main question that researchers want to answer is: • How long does it take for ALS symptoms to appear? Researchers will also learn more about: * How many participants develop ALS symptoms within 24 months of the start of Part B * Changes in participants' ability to perform their daily activities * Changes in participants' ability to breathe * How many participants die or need long-term breathing support * Changes in NfL levels in the blood * Changes in SOD1 protein levels in the fluid around the brain and spinal cord * How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug. The study will be done as follows: * Participants will first be screened to check if they can join the study. The screening period will be up to 6 weeks. Participants will join the study only after reading and signing an informed consent form, also known as an ICF. * In Part A, participants with presymptomatic ALS will not get any study drugs. Researchers will check the levels of NfL in their blood. Participants will be closely checked for any signs or symptoms of ALS. * Once a participant's NfL levels rise to a certain amount, they will move onto Part B. * In Part B, participants will be randomly assigned to get either tofersen or a placebo. Neither participants nor researchers will know who gets tofersen or the placebo during Part B. A placebo looks like the study drug but contains no medicine. * Participants will get the first 3 doses of tofersen once every 14 days. Afterwards, they will continue getting maintenance doses every 28 days. * All doses will be given through an intrathecal (IT) injection done through a lumbar puncture procedure. This involves injecting the drug into the fluid surrounding the spinal cord in the lower back. * Participants who develop ALS symptoms during Part B will move to Part C to receive tofersen. * Participants who develop ALS symptoms during Part A will move to Part D to receive tofersen. * In both Parts C and D, participants will know they are receiving tofersen. * Throughout the study, doctors will measure any changes to the participants' function and quality of life using different questionnaires. Doctors will also take blood and urine samples. They will also check the participants' overall health and ask how they are feeling. * Participants will have a follow-up visit 28 days after their last dose of study drug. * Participants will be in this study for up to about 6.5 years.

Conditions

  • Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

Interventions

  • TofersenDrug

    Administered as specified in the treatment arm

  • PlaceboDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B: Time to Emergence of Clinically Manifest ALSTime frame: Up to 5.6 years

Locations

32 sites in 14 countries. Site status is shown where the registry gives one.

  • HonorHealth Neurology

    Scottsdale, Arizona

  • University of California San Diego Medical Center

    La Jolla, California

  • California Pacific Medical Center Research Institute

    San Francisco, California

  • Holy Cross Hospital

    Fort Lauderdale, Florida

  • University of Miami School of Medicine

    Miami, Florida

  • The Emory Clinic

    Atlanta, Georgia

  • Northwestern Medicine

    Chicago, Illinois

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Massachusetts General Hospital, MA

    Charlestown, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical center

    New York, New York

  • Austin Neuromuscular Center

    Austin, Texas

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australia

  • UZ Leuven

    Leuven, Belgium

  • PSEG Centro de Pesquisa Clinica

    São Paulo, Brazil

  • Hospital Sao Paulo

    São Paulo, São Paulo, Brazil

  • University of Calgary

    Calgary, Alberta, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Genge Partners

    Montreal, Quebec, Canada

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, Paris, France

  • Universitaetsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

    Torino, Italy

  • Kagoshima University Hospital

    Kagoshima, Kagoshima-ken, Japan

  • University of Tokyo Hospital

    Bunkyō City, Tokyo-To, Japan

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland

  • NeuroProtect Sp. z o.o.

    Warsaw, Masovian Voivodeship, Poland

  • Hanyang University Seoul Hospital

    Seoul, South Korea

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Norrlands Universitetssjukhus

    Umeå, Sweden

  • University Hospital of Umea

    Umeå, Västerbotten County, Sweden

  • University of Sheffield

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.